Novavax starts Phase 1 clinical trial of coronavirus vaccine candidate Reuters

Novavax

Australian clinical research organization Nucleus Network announced Tuesday the commencement of dosing the first human participants for the Phase 1 trial of a COVID-19 vaccine on behalf of US -based biotechnology company Novavax.

App to help enrol COVID-19 patients into clinical trials developed...

KAZINFORM Thai COVID-19 vaccine research team on Monday said it will be recruiting human beings for vaccine trials later this year following an ongoing three months test on monkeys.

There are now more than 100 COVID-19 vaccine candidates in development globally, Ad5-nCoV is the first to be evaluated in humans.

"These results provide strong evidence that the vaccine candidate will be highly immunogenic in humans, leading to protection from COVID-19 and thus helping to control the spread of this disease", the assertion mentioned.


To get there, top vaccine makers have agreed to share data and lend the use of their clinical trial networks to competitors in the event their own candidate fails, the scientists said.

The most common adverse reactions were mild pain at the injection site reported in over half (54%, 58/108) of vaccine recipients, fever (46%, 50/108), fatigue (44%, 47/108), headache (39%, 42/108), and muscle pain (17%, 18/108).

A study published last Friday in the Lancet says the formulation from China's CanSino Biologics Inc. needs more trials to determine whether it can actually protect against SARS-CoV-2, the virus that causes COVID-19.

Within two weeks of vaccination, all dose levels of the vaccine triggered some level of immune response in the form of binding antibodies (that can bind to the coronavirus but do not necessarily attack it - low-dose group 16/36, 44%; medium dose 18/36, 50%; high dose 22/36, 61%), and some participants had detectable neutralizing antibodies against SARS-CoV-2 (low-dose group 10/36, 28%; medium dose 11/36, 31%; high dose 15/36, 42%). Novavax said it identified NVX-CoV2373 as its lead SARS-CoV-2 candidate following pre-clinical testing that demonstrated high immunogenicity and high levels of neutralising antibodies. So, we're trying to block that process. "We look forward to sharing the clinical results in July and, if promising, quickly initiating the Phase II portion of the trial". For the first time, this will include participants over 60 years old, an important target population for the vaccine. Also Read: China's "Batwoman": Coronavirus 'Just Tip of the Iceberg, ' More Pandemics May Arrive "Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global Covid-19 pandemic", said Stanley C. Erck, the president, and CEO of Novavax.

Related:

Comments

Latest news

Silent Hill returns in new Dead By Daylight DLC
Beahviour says it's open to any collaboration, regardless of the medium as long as it fits with the Dead by Daylight world. After a call, Cote said both parties realised this collaboration was the "perfect" crossover.

BlizzCon 2020 canceled with a possible replacement event coming early 2021
This could mean that there will be two BlizzCons next year, or that both will be merged into one. Blizzard was quick to adjust its workflow once the pandemic reached the U.S.

Ontario reports lowest number of new coronavirus cases in past two weeks
Ontario's number of COVID-19 cases has grown by 1.1 per cent from yesterday, the province's lowest growth rate since early March. On May 21, health officials confirmed 413 new cases and the number climbed to 441, 412 and 460 in the following days.

Weird 'American Horror Story' spinoff gets green light at FX
The image Murphy posted was fan-created from video interviews of the various cast members. Today, FX is also confirming the delay of season 10 into 2021.

France bans use of hydroxychloroquine to cure coronavirus
The evidence for the efficacy of hydroxychloroquine at treating COVID-19 has always been slim at best. It now simply states that clinical trials for potential covid-19 treatments remain ongoing .

Other news